Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.931 |
|---|---|
| High | 0.9605 |
| Low | 0.8009 |
| Bid | 0.81 |
| Offer | 0.85 |
| Previous close | 0.9755 |
| Average volume | 7.50m |
|---|---|
| Shares outstanding | 2.86m |
| Free float | 2.75m |
| P/E (TTM) | -- |
| Market cap | 2.41m USD |
| EPS (TTM) | -19.82 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Announcements
- AIM ImmunoTech Announces Commencement of Rights Offering
- AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
- AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
- AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
- AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering
- AIM ImmunoTech Announces Stock Dividend
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment
- AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series
- AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program
- AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
More ▼
